Related Experiment Videos
High-dose aprotinin in cardiac surgery--a prospective, randomized study
M J Swart1, P C Gordon, P B Hayse-Gregson
1Department of Cardiothoracic Surgery, Groote Schuur Hospital, Cape Town, South Africa.
Anaesthesia and Intensive Care
|October 1, 1994
Summary
High-dose aprotinin significantly reduced blood loss and homologous blood transfusion needs in patients undergoing primary cardiac surgery. This finding supports aprotinin
Area of Science:
- Cardiovascular Surgery
- Pharmacology
Background:
- Cardiac surgery, including coronary artery bypass and valve procedures, is associated with significant blood loss.
- Minimizing perioperative blood loss and transfusion requirements is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of high-dose aprotinin in reducing blood loss and transfusion requirements during primary cardiac surgery.
Main Methods:
- A randomized controlled trial involving 100 patients undergoing primary cardiac surgery.
- Patients received either high-dose aprotinin or a placebo.
- Postoperative blood loss and homologous blood transfusion rates were measured.
Main Results:
- Mean postoperative blood loss in the first six hours was significantly lower in the aprotinin group (172 ml) compared to the placebo group (321 ml).
- Fewer patients in the aprotinin group required homologous blood transfusions (16 vs. 7).
Conclusions:
- High-dose aprotinin effectively reduces blood loss and the need for blood transfusions in primary cardiac surgery.
- The findings contribute to the evidence supporting the use of aprotinin in managing perioperative bleeding in cardiac procedures.